The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 13.3% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 10% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 6%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (21 analysts) rates it buy, with a mean price target of $89.
Corteva CTVA
Clears both ethical standardsAn entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
In plain words · Corteva, Inc.
read at $87.58
Corteva holds its Markup at $87.58.
- PHPhase · the trend structure carries the Markup label
- INInsiders · no filings inside 60 days, left as found
- POPositioning · no disclosures inside 60 days, left as found
- OPOptions · no verdict drawn today, left as found
- SCScreen · passes the values gate
- edge confirmed
- edge broken
- edge forming
Each arm is one independent read. Conviction is not a single call, it is how many edges converge.
The investor read · the season, not the day
| Phase | Markup |
| Quantitative state | Consolidating, no directional conviction, held for 147 days |
| Price | $87.58 |
| Valuation | 47.34 trailing · 21.17 forward price to earnings |
| Values screen | PASS · score 90.0 |
| Beta | 0.56 |
The opportunity · what the numbers say it is worth
Our framework reads OVERVALUED — it trades above our $63.48 fair value estimate, narrow competitive moat, 11.00% revenue growth.
Price history & projections · where it has been, where the models see it going
The valuation journey · where the price sits against fair value and the Street
Green marks levels above today's price, red below; the shaded band is the gap between the price and our fair value.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish — a quality-at-a-fair-price name rather than a deep-value one.
| Revenue growth | 11.00% |
| Profit margin | 6.50% |
| Debt to equity | 13.64 |
| Analyst consensus | Buy · 20 covering |
Fair value and rating are our own model estimates; target range reflects third-party analyst estimates. Analysis, not advice.
The values screen, explained · five checks, plain English
This company clears both standards. There are two widely recognised ways to check whether a company is suitable for a Muslim investor. Here is how it did on each:
Used by most halal investing apps ✓ PASSES
The one Titan applies ✓ PASSES
What these two standards are, and how they differ →
- Business activity Its core business isn't built on prohibited lines — no gambling, alcohol, tobacco, weapons, or interest-based lending. Pass
- Debt load Interest-bearing debt is just 6.0% of its assets, well under the one-third ceiling — it does not run on borrowed money. Pass
- Interest-bearing cash Cash held in interest-bearing accounts and securities is 0.4% of assets, under the one-third limit. Pass
- Receivables Money owed to the company is 22.3% of assets, under the 49% limit. Pass
- Revenue purity Only 0.8% of revenue comes from non-compliant sources — under the 5% line. Pass
Every security is read against two recognised standards: our stricter asset-based screen (ratios measured against total assets) and the more widely used market-value standard (measured against market capitalisation). Where they agree we say so plainly; where they part ways — almost always on the debt check — we show both readings and mark it, because that disagreement is the finding, not a fault. We report the score; you and your scholar make the call.
The business, in plain words · what the numbers mean
Seeds and sprays priced for perfect harvests
Picture a farmer locking in next season's seed at a fat premium while the weather, pests and grain prices stay wild cards. Corteva sits in that spot right now. At 21 times forward earnings the shares trade well above our fair value with a negative margin of safety, and the narrow moat plus low single-digit ROE give little cushion when cycles turn.
The business splits between seeds and crop protection, both tied to farm incomes that swing with commodity prices and weather. Revenue growth looks solid at 11 percent, yet a 6 percent profit margin and 5 percent return on equity hardly scream durable advantage in a cyclical field. Analysts may cluster around a buy rating, but the valuation already prices in smooth sailing.
Cyclical names often flash cheap multiples at peak earnings; here the multiple is not cheap and the earnings can still fall fast. Currency moves, regulation on crop chemicals and sudden drops in planted acres all sit outside management control. Analysis, not advice.
| Forward P/E | 21.2x priced for continued growth |
| Trailing P/E | 47.3x expensive — the price assumes strong growth ahead |
| Revenue growth | 11.0% steady growth |
| Profit margin | 6.5% thin but positive margins |
| Return on equity | 5.1% a modest return on shareholder capital |
| Debt to equity | 0.14 minimal debt — a conservative balance sheet |
| Current ratio | 1.47 adequate liquidity, worth monitoring |
| Beta | 0.56 steadier than the market |
| Market cap | $58.6B |
| Employees | 21,500 |
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Latest news · what the market is reading on CTVA
- › Mission Produce's Farming Segment: Is a Recovery Underway? Zacks · 15d ago
- › NY Attorney General Sues 3M, Others Over ‘Forever Chemicals’ The Wall Street Journal · 19d ago
- › New York sues 3M, DuPont and other chemical companies over PFAS pollution Investing.com · 19d ago
- › 3M, DuPont, Corteva, Chemours Sued by New York AG Over Toxic Pollution From Consumer Products MT Newswires · 19d ago
- › What to Expect From Corteva's Next Quarterly Earnings Report Barchart · 19d ago
Headlines from third-party outlets, linked for reference — not our reporting, not advice.
Related securities · others in CTVA's space worth a look
Screened names in the same industry · explore each on its own page.
Where & how to trade · wherever in the world you are
CTVA trades on a US exchange. As a US-listed security it is accessible through almost any international broker offering US markets. New to this, or investing from outside the US? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The trader read · the latest dated commentary
The dated journal · newest first, never edited
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 10% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 6%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (21 analysts) rates it buy, with a mean price target of $89.
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score (90). The risk-adjusted return profile shows good risk-adjusted returns.
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with near-perfect ethical score (90). The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
The insider ledger · Form 4 filings, as filed
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-30 | GIESSELMAN JANET PLAUT | Director | 95 | $7,750 | |
| 2026-04-30 | NAYYAR NAYAKI R | Director | 401 | $32,500 | |
| 2026-04-28 | GIESSELMAN JANET PLAUT | Director | 2,350 | · | |
| 2026-04-28 | PAGE GREGORY R | Director | 3,870 | · | |
| 2026-04-28 | EVERITT DAVID C | Director | 2,350 | · | |
| 2026-04-28 | WARD PATRICK J | Director | 2,350 | · | |
| 2026-04-28 | PREETE KERRY J | Director | 2,350 | · | |
| 2026-04-28 | POLICINSKI CHRISTOPHER J | Director | 2,350 | · | |
| 2026-04-28 | LUTZ MARCOS M | Director | 2,350 | · | |
| 2026-04-28 | NAYYAR NAYAKI R | Director | 2,350 | · |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
The political ledger · congressional disclosures
| Date | Politician | Party | Type | Amount |
|---|---|---|---|---|
| 2026-04-13 | Ro Khanna | Democrat | Purchase | 1K–15K |
| 15 May2026 | Ro Khanna | Democrat | sell | 1K–15K |
What holding actually paid · price plus dividends
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $82.64 | -9.1% | $0.18 | $912 | -8.8% |
| 2 months | $83.64 | -10.1% | $0.18 | $901 | -9.9% |
| 3 months | $79.57 | -5.5% | $0.18 | $947 | -5.3% |
| 6 months | $65.74 | +14.3% | $0.36 | $1,149 | +14.9% |
| 1 year | $70.86 | +6.1% | $0.72 | $1,071 | +7.1% |
| 2 years | $50.66 | +48.4% | $1.40 | $1,511 | +51.1% |
| 3 years | $54.61 | +37.6% | $2.04 | $1,414 | +41.4% |
| 5 years | $42.19 | +78.1% | $3.20 | $1,857 | +85.7% |
Historical returns from market close data. Past performance does not guarantee future results.